Changes/additions to materials (reviewed 15/06/12):
DVLA blood glucose monitoring requirements for people with diabetes
Rapid Review No.4937 has been produced to help clarify the DVLA requirements and advice for the monitoring of blood glucose in people with diabetes. It is based on the DVLA publication ‘At a glance guide to the current medical standards of fitness to drive’ and additional correspondence between the DVLA and the NPC.
New insulin safety guidance
Since these materials were published, the NPSA has issued a Rapid Response Report: Safer administration of insulin, which outlines supporting information aimed at reducing the number of wrong dose incidents involving insulin. This information has been summarised in NPC Rapid Review No. 1705
Insulin glargine and possible cancer link
In the September 2009 edition of Drug Safety Update, the MHRA and CHM noted that observational studies have suggested a possible association between insulin glargine and an increased risk of cancer. The results are not entirely consistent, and can neither confirm nor exclude a relationship between insulin glargine and cancer. Therefore, the European Medicines Agency (EMEA) has advised that no change in recommendations for use is required at present. Please see MeReC Rapid Review No. 374 for a discussion of this evidence and the very high cost of insulin glargine.
Test your knowledge (or just have some fun) by answering the questions in this quiz. Suggested answers are given after each question with some additional information and references. You even get a score at the end that you can print out and put in your CPD folder!
To reveal the answer to the quiz questions click on the arrow button at the bottom. The answer will then appear, however, you may need to use the slider on the right hand side of the page to reveal the whole text.